To test whether αCBSF suppresses β-site APP-cleaving enzyme 1 (BACE1)-mediated APP processing in vivo, 4-mo-old 3xTg-AD mice were treated αCBSF, AgBSF (0.5 μg/mouse), or PBS control (1 μL/mouse) with i.c.v. injections. This evidence concerns the gene BACE1 and Alzheimer disease.